|
|
 | | | |
- close
- close
- close
- close
This excerpt taken from the GSK 20-F filed Feb 29, 2008. Seroxat/Paxil in
both regions. International sales grew 6% which included 4% growth in Paxil in
Japan. Total This excerpt taken from the GSK 6-K filed Mar 22, 2007. Seroxat/Paxil sales grew 4% to £620 million, due to strong growth of Paxil CR in the US and Paxil IR in Japan partly offset by generic competition to Paxil IR in Europe.
Total Wellbutrin sales grew 24% to £900 million due to the performance of Wellbutrin XL, a new once-daily product, which grew 25% to £798 million. A generic competitor to the Wellbutrin XL 300mg tablet (approximately 60% of Wellbutrin sales) entered the US market in December 2006.
This excerpt taken from the GSK 20-F filed Mar 2, 2007. Seroxat/Paxil. In certain markets litigation with Synthon is ongoing and Synthon is asserting counterclaims
for unfair competition against the Group.
Generic products containing the anhydrate form of paroxetine hydrochloride are now on the market in most European countries. Whilst some of these products are the subject of continuing litigation, most actions have now been settled and it is expected that more will be settled in the future. In the UK, litigation of several years standing between the Group and Apotex culminated in an Appeal Court decision that the Group’s anhydrate process patent was valid but not infringed. Following the litigation in Canada with Apotex over several other patents related to paroxetine, Apotex launched its generic product in Canada in October 2003. Apotex alleged that as a result of that litigation it had been enjoined from launching that product after receipt of regulatory approval. An action by Apotex to recover damages related to the delay occasioned by those injunctions is ongoing. Paxil CR | EXCERPTS ON THIS PAGE:
RELATED TOPICS for GSK: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||
